ORPHA:36387
Genetic epilepsy with febrile seizure plus
Also known as: GEFS+ · Generalized epilepsy with febrile seizures plus
Publications
25,723
Trials
0
Interventional, condition-specific
Researchers
1,397
Distinct authors in sample
Gene link
HCN1, SCN1A, SCN1B
Definitive
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare familial syndrome characterized by febrile, focal and generalized , with a spectrum of phenotypes largely variable among different family members.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018214
- MeSH:C565808
- UMLS:C3502809
- NCIT:C122811
Additional Mondo synonyms (5)
epilepsy, generalized, with febrile seizures plus · generalised epilepsy with febrile seizures-plus · generalized epilepsy with febrile seizures plus · genetic epilepsy with febrile seizures plus · genetic epilepsy with febrile seizures-plus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No matched interventional trial, but a gene association and an animal model are on record — often described as translation-ready / stalled at the clinical step.
- Gene identifiedPresent
Definitive — HCN1, SCN1A, SCN1B, STX1B
- LiteraturePresent
25,723 matched papers (14,603 in last 10 years) Source
- Phenotype characterisedPresent
81 HPO annotations (e.g. EEG with spike-wave complexes (>3.5 Hz); Febrile seizure (within the age range of 3 months to 6 years); Bilateral tonic-clonic seizure) Source
- Animal modelPresent
7 genotype models (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (HCN1, SCN1A, SCN1B…).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
81
Associated phenotypes · MONDO:0018214
- EEG with spike-wave complexes (>3.5 Hz)
- Febrile seizure (within the age range of 3 months to 6 years)
- Bilateral tonic-clonic seizure
- Generalized non-motor (absence) seizure
Showing 4 of 81 — open Monarch for the full list.
Animal models (Monarch / Alliance)
7
Model associations linked to this Mondo ID
- Kcnq2Nmf134/Kcnq2+ Scn1atm1.1Aesc/Scn1a+ [background:] involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6J·MGI:4950073·Mus musculus
- Gabrg2tm1.2Rmac/Gabrg2+ [background:] involves: C57BL/6 * C57BL/6J * SJL·MGI:6740192·Mus musculus
- Scn1atm1.1Aesc/Scn1a+ Tg(Eno2-Scn2a1*)Q54Mm/0 [background:] involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6J * SJL/J·MGI:4950072·Mus musculus
- Scn1atm1.1Aesc/Scn1atm1.1Aesc [background:] involves: 129X1/SvJ * C57BL/6J * SJL·MGI:4458389·Mus musculus
- Scn1atm1.1Aesc/Scn1a+ [background:] involves: 129X1/SvJ * C57BL/6J * SJL·MGI:4458390·Mus musculus
- Tg(Scn1a*)RH9Aesc/0 [background:] involves: FVB/NJ·MGI:3851211·Mus musculus
- Scn1btm1.1Bion/Scn1b+ [background:] Not Specified·MGI:4830676·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
25,723
25,723 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
25,723 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
14,603 in the last 10 years · low confidence
Phrase hits: 14,888 · MeSH hits: 0
Who's working on it?
1,397
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Scheffer IE11 papers · 2025
Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria 3084, Australia; Florey Institute and Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Parkville, Victoria 3052, Australia.
Papers in Europe PMC - 02Berkovic SF10 papers · 2025
Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria 3084, Australia.
Papers in Europe PMC - 03Helbig I8 papers · 2026
Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America.
Papers in Europe PMC - 04Wang Y8 papers · 2026
Department of Neurology, Comprehensive Epilepsy Center, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Papers in Europe PMC - 05Guerrini R7 papers · 2026
Pediatric Neurology Unit and Laboratories, A. Meyer Children's Hospital -University of Florence, Florence, Italy.
Papers in Europe PMC - 06Li X7 papers · 2026
Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Papers in Europe PMC - 07Møller RS7 papers · 2026
Department of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Center, Filadelfia, Dianalund, Denmark.
Papers in Europe PMC - 08Ding J6 papers · 2026
The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China; Department of Pediatrics, Guangdong Provincial People's Hospital, Guangzhou 510080, China; Department of Pediatrics, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, 523059, China.
Papers in Europe PMC - 09Afawi Z5 papers · 2025
Sackler School of Medicine, Tel-Aviv University, Ramat Aviv, Israel.
Papers in Europe PMC - 10Brunklaus A5 papers · 2025
Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 5 · after dedupe 5 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 5 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (5)
- ctis·2025-524448-36-00·Authorised·A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
skipped — LLM skipped (--skip-llm)
- ctis·2025-522191-86-00·Authorised, recruiting·A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants
skipped — LLM skipped (--skip-llm)
- ctis·2024-511775-15-00·Authorised, ongoing·A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)
skipped — LLM skipped (--skip-llm)
- ctis·2023-505497-14-00·Authorised, ongoing·A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (EPPIK)
skipped — LLM skipped (--skip-llm)
- ctis·2023-504597-37-00·Expired·A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Genetic epilepsy with febrile seizure plus — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Genetic epilepsy with febrile seizure plus" OR "GEFS+" OR "Generalized epilepsy with febrile seizures plus" OR "epilepsy, generalized, with febrile seizures plus" OR "generalised epilepsy with febrile seizures-plus" OR "genetic epilepsy with febrile seizures plus" OR "genetic epilepsy with febrile seizures-plus") OR ("HCN1" OR "HCN1 syndrome" OR "HCN1-related" OR "SCN1A" OR "SCN1A syndrome" OR "SCN1A-related" OR "SCN1B" OR "SCN1B syndrome" OR "SCN1B-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Genetic epilepsy with febrile seizure plus" OR "GEFS+" OR "Generalized epilepsy with febrile seizures plus" OR "epilepsy, generalized, with febrile seizures plus" OR "generalised epilepsy with febrile seizures-plus" OR "genetic epilepsy with febrile seizures plus" OR "genetic epilepsy with febrile seizures-plus"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (25723) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T23:54:01.420Z
